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Association of plasminogen activator inhibitor-1 4G/4G geno- Type 2 diabetic nephropathy has imposed a major
type and type 2 diabetic nephropathy in Chinese patients. health burden in developed countries. Great variations
Background. Plasminogen activator inhibitor-1 (PAI-1) is a in the incidence of diabetic nephropathy among different
key regulator of fibrinolytic pathway and extracellular matrix
ethnic groups have been observed. The importance of(ECM) turnover. Because diabetic nephropathy is character-
strict metabolic and blood pressure control has been wellized by the presence of basement membrane thickening and
mesangial expansion, we examined the role of PAI-1 gene established for the prevention of the development and
polymorphisms in the development of type 2 diabetic nephrop- progression of diabetic nephropathy in these patients
athy. Evidence also suggested that the PA/plasmin system and [1]. However, the role of genetic factors remains to be
the renin-angiotensin system (RAS) interact together to affect
defined.the risk of fibrosis and thrombosis. Hence, we also studied the
With knowledge of the renoprotective effect of angio-synergistic effect between PAI-1 and angiotensin-converting
tensin-converting enzyme (ACE) inhibitor in diabeticenzyme (ACE) gene polymorphisms.
Methods. The PAI-1 and ACE (D/I) gene polymorphisms nephropathy, the renin-angiotensin system (RAS) gene
were examined in a cohort of Chinese type 2 diabetic patients polymorphisms, including ACE D/I and angiotensinogen
who had diabetes for an average of 14 years. These patients M235T gene polymorphisms, have been investigated
were sex and age matched. Group A (N 5 46) consisted of
among different populations. A recent meta-analysispatients without diabetic nephropathy (normoalbuminuric
failed to confirm an association between ACE D/I genewith creatinine ,120 mmol/L), and group B (N 5 95) was with
polymorphisms and diabetic nephropathy in Caucasians,diabetic nephropathy (with albuminuria or renal impairment,
including patients on dialysis). although its role cannot be totally excluded in the Asian
Results. Patients with type 2 diabetic nephropathy had a population [2]. Studies of other RAS gene polymor-
higher frequency of PAI-1 (4G/4G) genotypes than those with- phisms did not give conclusive results either [3, 4].out nephropathy [4G/4G:4G/5G:5G/5G 5 41:38:21 (%) vs.
Diabetic nephropathy is characterized by the presence15:65:20(%), P 5 0.005]. Diabetic patients with coexistence of
of basement membrane thickening and mesangial expan-PAI-1 4G/4G genotype and ACE D alleles had a higher inci-
dence of diabetic nephropathy (22 vs. 7%, P 5 0.012) than those sion. Large acellular accumulations with the formation
with other combinations of genotypes. Multivariate logistic of Kimmelstiel–Wilson nodules are seen under light mi-
regression analysis showed that PAI-1 4G/4G (P 5 0.01) and croscopy. Pathological accumulation of mesangial extra-
the prevalence of hypertension (P , 0.0001) are independent cellular matrix (ECM) is important in the progression ofrisk factors of development of type 2 diabetic nephropathy.
glomerulosclerosis [5]. The exact pathogenesis of ECMConclusions. These results suggest that the PAI-1 4G/4G
accumulation and modeling is unknown, but the fibrino-genotype is associated with an increased risk for type 2 diabetic
nephropathy in Chinese patients, which is an independent risk lytic pathway is believed to play an important role [6].
factor for the development of nephropathy. The PAI-1 4G/4G One of the key regulators of fibrinolysis in our body is
genotype also exhibits a synergistic effect with the ACE D the plasminogen activator (PA)/plasmin system. Plas-
allele on development of diabetic nephropathy.
minogen is activated by tissue plasminogen activator
(t-PA) and urokinase (u-PA) to plasmin and produces
active matrix metalloproteinase-2 (MMP-2), both ofKey words: type 2 diabetes mellitus, PAI-1 gene, angiotensin con-
verting enzyme gene, gene polymorphism. which promote the degradation of matrix. This process
is counterbalanced by plasminogen activator inhibitor-1Received for publication May 4, 1999
(PAI-1), which inactivated t-PA and u-PA, resulting inand in revised form August 9, 1999
Accepted for publication September 9, 1999 a decreased production of plasmin and hence an accumu-
lation of intercellular matrix. Both PA and PAI-1 areÓ 2000 by the International Society of Nephrology
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expressed in the glomeruli [7], and a delicate balance of was on antihypertensive drugs. Fundal examination was
performed by ophthalmologist or physician, and diabeticwhich is important in the regulation of mesangial matrix
turnover. Genetic variation in PAI-1 gene is associated retinopathy was defined as the presence of proliferative
or background diabetic retinopathy. HbA1c was mea-with different levels of serum PAI-1 activity [8]. PAI-1
4G/4G is associated with the highest serum PAI-1 activ- sured by an automated ion-exchange chromatographic
method (reference range, 5.1 to 6.4%; Bio-Rad, Her-ity and PAI-1 5G/5G with the lowest level. Moreover,
recent studies also suggested a synergistic effect between cules, CA, USA). Urinary albumin concentrations were
measured by immunoturbidimetry [10]. Twenty-four–RAS and PA/plasmin system in the pathogenesis of car-
diovascular disease and macroangiopathy [9]. Here we hour urinary albumin excretion (UAE) was measured
on three occasions during a six-week period. For patientsstudied the effect of PAI-1 gene polymorphisms and its
synergistic effect with the ACE D/I genotype on the who were anuric (those on dialysis), all of them were
macroalbuminuric at the time of diagnosis of renal dis-development of type 2 diabetic nephropathy among Chi-
nese patients. ease and fulfill the previously mentioned criteria of dia-
betic nephropathy, which are defined earlier in this arti-
cle. Increased UAE was defined as a 24-hour UAE .30
METHODS
mg/day on at least two of the three occasions. Microal-
This was a cohort study performed in the Prince of buminuria and macroalbuminuria were defined as a
Wales Hospital in Hong Kong. Type 2 diabetic patients UAE of 30 to 300 and .300 mg/day, respectively.
with more than a 10-year history of disease who were
followed up at the diabetes clinic or renal clinic were Angiotensin-converting enzyme gene polymorphisms
assessed. We compared sex- and age-matched type 2 Genomic DNA was extracted by standard phenol/
diabetic patients with and without diabetic nephropathy, chloroform methods from peripheral blood collected on
despite similar duration of disease, control of risk factors, ethylenediaminetetraacetic acid (EDTA; pH 5 8). The
including glycemic and blood pressure control and usage ACE I/D gene polymorphism was determined by poly-
of ACE inhibitor. Diabetes was defined as fasting a merase chain reaction (PCR) using primers flanking the
plasma sugar .7.8 mmol/L or two-hour postload plasma polymorphic region of intron 16 with the following
sugar .11.1 mmol/L. Group A (N 5 45) consisted of primer sequences: 59-CTG GAG ACC ACT CCC ATC
type 2 diabetic patients with a history of more than 12 CTT TCT-39 and 59-GAT GTG GCC ATC ACA TTC
years of diabetes without diabetic nephropathy (serum GTC AGA T-39. Reactions were carried out in 50 mL
creatinine ,120 mmol/L and normoalbuminuric). Group volumes under standard conditions (3 mmol/MgCl2, 500
B consisted of sex- and age-matched patients (N 5 96) mmol/L for each dNTP, 10 mmol/L Tris/HCl, 50 mmol/L
with diabetic nephropathy, including those on dialysis. KCl, 0.2 mmol/L primers, 1 U Taq DNA polymerase
Patients were defined as having diabetic nephropathy if per sample) with a Cetus thermocycler and one-minute
they had renal biopsy-confirmed diabetic nephropathy denaturing time (948C), one-minute annealing time
or the presence of diabetic retinopathy and neuropathy (588C), and one-minute extending time (728C) for a total
at the onset of renal disease when they presented with of 30 cycles. Electrophoresis of the amplified products
microalbuminuria or macroalbuminuria, irrespective of in 2% agarose gel allowed detection of a 190 bp fragment
their renal function. Patients with renal biopsy showing (deletion) and of a 490 bp fragment (insertion). Mis-
other types of glomerulonephritis, a history of renal typing between the DD and DI genotypes was overcome
stones, a single kidney, contrast or drug-induced ne- by a second allele-specific PCR, which identified the
phropathy, or the absence of retinopathy at the onset of presence or absence of the I allele.
renal disease were excluded. Atypical features such as
Plasminogen activator inhibitor-1 4G/5G promotershrunken kidneys or significant microscopic hematuria
polymorphism genotypingor those with renal disease without diabetic retinopathy
were included only if the biopsy confirmed diabetic ne- Genomic DNA was extracted from peripheral blood
phropathy as the sole renal disease (comprised of 10% leukocytes of all 141 type 2 diabetic patients and 95
of group B patients). Macrovascular complications are normal controls by standard techniques. PAI-1 4G/5G
recorded from history. Ninety-five nondiabetic Chinese promoter genotype polymorphism was determined by
subjects were used as the control. PCR amplification of genomic DNA of all the subjects
During the visits, fasting blood samples were checked using the allele-specific primers: (a) insertion 5G allele,
for glucose, HbA1c, and lipids. Arterial blood pressure 59-GTC TGG ACA CGT GGG GG-39, and (b) deletion
was measured after five minutes of rest using a standard 4G allele, 59-GTC TGG ACA CGT GGG GA-39. Each
sphygmomanometer. Hypertension was defined as a sys- in combination with a common downstream primer
tolic blood pressure or diastolic blood pressure .140 59-TGC AGC CAG CCA CGT GAT TGT CTA G-39
gives rise to a 139 bp DNA fragment. A control upstreammm Hg or 90 mm Hg, respectively, or if the patient
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to compare continuous data among patients with differ-
ent PAI-1 genotypes. Multivariate logistic regression
with two-way analysis was used for analysis of indepen-
dent risk factor of diabetic nephropathy. A P value of
,0.05 (two-tailed) was considered significant.
RESULTS
Characteristics of patient populations
The baseline characteristics of both groups of patients
are shown in Table 1.
They had a similar duration of diabetes mellitus, age,
sex distribution, body mass index (BMI), HbA1c, preva-
lence of ACE inhibitor usage, and blood pressure con-
trol. All patients in group A (without diabetic nephropa-
thy) were normoalbuminuric with normal renal function.
Twenty percent (9 out of 45) of them have diabetic reti-
nopathy. Eighty-four percent (80 out of 95) of patients
in group B (with diabetic nephropathy) have diabetic
retinopathy, and 43% (41 out of 95) of them required
renal replacement therapy. Eighteen percent (17 out of
Fig. 1. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism 95) of patients in group B were microalbuminuric, andof five patients. The amplified DNA of 5G polymerase chain reaction
39% (37 out of 95) were macroalbuminuric. Patients withusing the “Insertion” primers is shown in the upper panel and that
of 4G using the “Deletion” primers in the lower panel. Patient 1 is diabetic nephropathy (group B) have a higher choles-
homozygous for 5G/5G. Patients 2 and 4 are homozygous 4G/4G. Pa- terol level and triglyceride level than those withouttients 3 and 5 are heterozygous 4G/5G. Abbreviations are: M, molecular
(group A). No significant differences were found in theweight marker; pc, positive control.
baseline characteristics of patients with different PAI-1
genotypes (Table 2). The prevalence of diabetic ne-
phropathy is highest among patients with the PAI-1
primer 59-AAG CTT TTA CCA TGG TAA CCC CTG 4G/4G genotype compared with those with the 4G/5G
GT-39 was used as positive control in the PCR [11]. and 5G/5G genotypes [(4G/4G), 84% vs. (4G/5G), 56%
A 25 mL PCR mixture contained 50 pmol allele-spe- vs. (5G/5G), 68%; P 5 0.005].
cific primer, a 50 pmol common downstream primer, a
Difference in distribution of PAI-1 gene2.5 pmol control upstream primer, 1 3 PCR buffer, 2.0
polymorphisms among patients with and withoutmmol/L magnesium chloride, 0.2 mmol/L dNTPs, and
diabetic nephropathy1.25 U Taq polymerase. All of the reagents required
for PCR were purchased from Boehringer Mannheim The allele frequencies and the genotype distribution
(Mannheim, Germany). The thermal cycling conditions of the PAI-1 gene polymorphism are shown in Table 3.
were 948C for 45 seconds, 678C for 45 seconds, and 728C A higher prevalence of PAI-1 4G/4G genotype was ob-
for 75 seconds for 30 cycles. The PCR products were served among patients with diabetic nephropathy than
separated by gel electrophoresis in 2% agarose gel those without [4G/4G 5 41% (with nephropathy) vs.
(GIBCO, Grand Island, NY, USA), which had been 15% (without nephropathy), P 5 0.005]. The values pre-
stained with ethidium bromide and viewed under ultravi- dicted by the assumption of the Hardy–Weinberg equi-
olet irradiation. Each subject was classified into 4G/4G, librium in both groups [(4G/4G):(4G/5G):(5G5G) 5
4G/5G, or 5G/5G according to the presence of the 139 36%:48%:16% (with nephropathy) vs. 23%:50%:27%
bp PCR product generated by the two allele-specific (without nephropathy), P 5 NS] were similar to those
primers (Fig. 1). observed. There was no difference in the distribution of
PAI-1 genotypes in group A and group B patients in com-
Statistical analysis parisons with the control group [(4G/4G):(4G/5G):
Results are expressed as mean 6 SD for normally (5G5G) 5 33%:48%:19% (control), P 5 NS]. Frequen-
distributed data and median (range) for skewed data. cies of 4G and 5G alleles were not different among pa-
Statistical significance was tested using unpaired Stu- tients with and without diabetic nephropathy [4G allele
dent’s test and Mann–Whitney test as appropriate. Com- frequency:5G allele frequency 5 60%:40% (with ne-
parisons between groups were performed using the chi- phropathy) vs. 48%:52% (without nephropathy), P 5
NS]. Multivariate logistic regression analysis was per-square test. A one-way analysis of variance test was used
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Table 1. Clinical and biochemical characteristics of Chinese type 2 diabetic patients with or without diabetic nephropathy
Group A Group B
without nephropathy with nephropathy P value
No of patients 46 95 NS
Sex M:F 27:73 36:64 NS
Age years 62611 62610 NS
Duration of DM years 13.564.4 13.665.4 NS
BMI kg/m2 24.663.7 24.063.2 NS
Creatininea lmol/L 71(45–107) 588(51–1737) ,0.0001
Hb g/dL 13.861.5 10.562.6 0.001
HbA1c % 8.761.8 7.861.7 NS
Systolic BP mm Hg 138619 152625 NS
Diastolic BP mm Hg 8168.2 80611 NS
Mean BP mm Hg 100610 104613 NS
Cholesterol mmol/L 5.560.9 5.761.2 0.02
Triglycerides mmol/L 1.5260.86 2.6362.06 ,0.001
HT % 46 87 ,0.0001
IHD % 6 18 0.03
CHF % 0 15 0.005
Stroke % 2 6 NS
Microalbuminuria % 0 18
Macroalbuminuria % 0 39
Retinopathy % 20 84 ,0.0001
On ACE I % 9 21 NS
Patient on dialysis % 0 43 ,0.0001
a In median (range)
Table 2. Characteristics and biochemical parameters of different plasminogen activator inhibitor-1 (PAI-1) genotypes
PAI-1 PAI-1 PAI-1
4G/4G 4G/5G 5G/5G P value
N 47 66 28
Age years old 63610 60610 63611 NS
Sex M:F 33:67 40:60 29:71 NS
Duration of DM years 13.164 1466 1465 NS
BMI kg/m2 24.163.4 24.863.6 24.263.2 NS
With stroke % 2 3 10 NS
HbA1C % 8.361.8 8.161.8 7.961.8 NS
Hb g/dL 11.563.0 11.962.6 11.362.5 NS
Cholesterol mmol/L 5.861.0 5.661.2 5.461.2 NS
Triglycerides mmol/L 2.3461.44 2.1361.90 1.2762.0 NS
Creatininea lmol/L 124(45–1653) 90(45–1737) 140(53–1672) NS
With hypertension % 85 67 70 NS
On dialysis % 26 32 37 NS
With congestive heart failure % 8 10 14 NS
With retinopathy % 67 58 54 NS
With ischemic heart disease % 20 15 11 NS
With nephropathy % 84 56 68 0.005
a In median (range)
formed with sex, age, duration of diabetes, hypertension,
cholesterol level, HbA1C, PAI-1 genotypes, and syner-
Table 3. Distributions of plasminogen activator inhibitor-1 gistic effect between PAI-1 and ACE D/I genotypes,
(PAI-1) gene and allele frequencies in Chinese type 2 diabetic
which showed that the presence of hypertension (P ,patients with or without diabetic nephropathy
0.0001) and PAI-1 4G4G genotype (P 5 0.01) was an
Group A Group B independent risk factor for the development of diabeticwithout nephropathy with nephropathy P
nephropathy. The adjusted odds ratio for the presence
N 46 95
of PAI-1 4G/4G genotype was 1.85 (CI, 1.35 to 2.15)PAI-1 genotypes
4G/4G 15% (7) 41% (39) 0.005 and for presence of hypertension was 2.75 (2.27 to 3.23)
4G/5G 65% (30) 38% (36) for the development of diabetic nephropathy. The rela-
5G/5G 20% (9) 21% (19)
tionship persisted even when only patients with normalAllele frequency
4G 48% 60% NS renal function (, 120 mmol/L) were included for analysis
5G 52% 40% [(4G/4G):(4G/5G):(5G5G) 5 57%:29%:14% (with ne-
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Table 4. Distributions of plasminogen activator inhibitor-1 (PAI-1) gene and allele frequencies in Chinese type 2 diabetic patients with or
without diabetic nephropathy (with patients on dialysis excluded)
Group B
Group A with nephropathy
PAI-1 genotypes without nephropathy (non-dialyzed patients) P value
N 46 52
4G/4G 7 (15%) 28 (54%) 0.00025
4G/5G 30 (65%) 15 (29%)
5G/5G 9 (20%) 8 (17%)
Table 5. Distribution of different combinations of plasminogen or without retinopathy. Moreover, there was no syner-
activator inhibitor-1 (PAI-1) and angiotensin converting enzyme
gistic effect between PAI-1 (4G/5G) and ACE (D/I)D/I genotypes in Chinese type 2 diabetic patients with or without
diabetic nephropathy genotypes on the risk of diabetic retinopathy.
Group A
without Group B
DISCUSSIONCombinations of genotypes N nephropathy with nephropathy
The plasminogen activator/plasmin system plays a piv-4G4G/DD/DI 23 3 (7%)a 20 (22%)a
4G4G/II 21 4 (9%) 17 (19%) otal role in the regulation of fibrinolysis and ECM turn-
4G5G/5G5G/DD/DI 49 21 (48%) 28 (30%) over. The genetic variation in the PAI-1 gene is associ-4G5G/5G5G/II 43 16 (36%) 27 (29%)
ated with varying levels of PAI-1 activity in healthy
a P 5 0.03
individuals, in patients with coronary artery disease [12],
and in patients with diabetes mellitus [13]. Besides, Da-
won et al also suggested that the 4G allele is associated
with an increased transcription rate in HepG2 cells underphropathy) vs. 15%:65%:20% (without nephropathy),
interleukin-1 stimulation [14]. The frequencies of PAI-1P 5 0.0006]. This is also true when patients on dialysis
(4G/5G) genotype and 4G allele of our Chinese diabeticwere excluded from the analysis (Table 4).
patients (4G/4G:4G/5G:5G/5G: 5 33%:47%:20%, 4G
Synergistic effect between the ACE D allele and allele frequency 5 60%) were similar with that reported
PAI-1 4G4G genotype on the development of in Caucasian (4G/4G:4G/5G:5G/5G: 5 35%:51%:14%,
diabetic nephropathy 4G allele frequency 5 60%) and Japanese type 2 diabetic
patients (4G/4G:4G/5G:5G/5G: 5 31%:56%:13%, 4GThe distribution of different combinations of ACE
allele frequency 5 60%) [9, 15].(D/I) and PAI-1 (4G/5G) genotypes is shown in Table
The role of the PAI-1 genotype in the pathogenesis5. Coexistence of ACE D allele and PAI-1 4G4G was
and progression of diabetic nephropathy has recentlyassociated with increased risk of type 2 diabetic nephrop-
been addressed, and no relationship was found betweenathy [prevalence of 4G/4G and D allele, 22% (with ne-
PAI-1 gene polymorphisms and advanced diabetic ne-phropathy) vs. 7% (without nephropathy), P 5 0.03].
phropathy among type 2 diabetic Japanese patients [9].The difference still held when only patients with normal
In our study, a higher prevalence of PAI-1 4G/4G geno-renal function (,120 mmol/L) were included for analysis
type was found among patients with diabetic nephropa-[prevalence of 4G/4G and D allele, 36% (with nephropa-
thy compared with a group of sex- and age-matched typethy) vs. 7% (without nephropathy), P 5 0.001]. The odds
2 diabetic patients with a similar duration of disease,ratio for diabetic nephropathy in patients with coexisted
blood pressure, and glycemic control. This does not con-D allele and 4G/4G genotype was 1.40 (CI, 1.10 to 1.70)
tradict previous findings [9] because we were studyingin univariate analysis as compared with those with other
the effect of PAI-1 genotypes on the prevalence of dia-combinations of genotypes.
betic nephropathy, as defined by the presence of albu-
Effect of PAI-1 gene polymorphisms on minuria (microalbuminuria or macroalbuminuria) rather
diabetic retinopathy than the progression of diabetic nephropathy in the rela-
tionship to the renal function. The association of PAI-1Diabetic retinopathy was highly prevalent in both
4G/4G genotype with diabetic nephropathy still upheldgroups of patients with the long duration of diabetes.
when only patients with normal renal function (,120Eighty-four percent of the patients with diabetic ne-
mmol/L) were included for analysis. This showed thatphropathy had retinopathy, whereas only 20% of pa-
the genotype is associated with the development of albu-tients without significant nephropathy had retinopathy
minuria, which is the hallmark of diabetic nephropathy.(P , 0.0001). There were no differences in the distribu-
tion of PAI-1 (4G/5G) genotypes between patients with Multivariate regression model analysis with HbA1C,
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BMI, cholesterol, hypertension, age, sex, and duration for metabolic factors such as lipids and HbA1C. Never-
of diabetes controlled also confirmed that the PAI-1 theless, more studies are required to elucidate the mech-
4G/4G genotype was an independent risk factor for the anism of interaction between the PAI-1 and ACE geno-
development of nephropathy in type 2 diabetic patients. types in disease pathogenesis in the body.
The prevalence of patients on dialysis and the median The PAI-1 gene polymorphism was associated with a
of serum creatinine were similar among patients with higher risk of diabetic retinopathy in Pima Indians [21].
different PAI-1 genotypes, although patients with PAI-1 However, no relationship was found between PAI-1 ge-
4G/4G had a higher prevalence of diabetic nephropathy notypes and retinopathy in Caucasian diabetic patients
than other genotypes (Table 2). This may be due to the [22]. We also failed to confirm the relationship. It is
fact that the effect of PAI-1 4G/4G genotype is mainly speculative whether there is any genetic difference in
on the development of diabetic nephropathy rather than Pima Indians comparing with Chinese in the effect of
the progression of diabetic nephropathy. Moreover, PAI-1 gene polymorphisms on the development of reti-
some of the patients with PAI-1 4G/4G genotypes and nopathy. However, one of limitations of these cross-
advanced renal failure may have higher premature death sectional genetic studies may be due to population ad-
rates or a tendency to be excluded from renal replace- mixture, and other study designs, for example, affected
ment therapy, hence giving rise to the observed results. sib-pair analysis and transmission disequilibrium test in-
The PAI-1 4G/4G genotype was found to be associated volving families affected with the disease, may be useful
with an increased risk of macroangiopathy in diabetic in confirming the findings [23].
patients [15]. Our macroangiopathy rates were not differ- The high prevalence of nephropathy in Chinese type
ent among patients with different genotypes. This may 2 diabetic patients has been a heavy burden to the health
be due to the limitation of a study design with potential care system because as many as 50% of type 2 diabetic
selection bias caused by premature death as a result of patients were reported to have proteinuria [24], and
cardiovascular or cerebrovascular events in those with many of these patients will progress to end-stage renal
adverse genotypes. failure and require dialysis. Apart from glycemic and
The interaction between the PA/plasmin system and blood pressure control, genetic polymorphism probably
metabolic control is intriguing. Serum PAI-1 activity is plays an important role. We found that the PAI-1 4G/4G
found to be positively correlated with metabolic indices, genotype is associated with an increased risk of diabetic
including fasting glucose, cholesterol, triglycerides, and nephropathy in type 2 diabetic patients, and a synergistic
BMI, in type 2 diabetic patients [13, 16]. This correlation effect with the ACE D allele was also demonstrated.
was strongest among the PAI-1 4G/4G genotype group. Nevertheless, longitudinal studies are still required for
Hence, patients with the PAI-1 4G/4G genotype may be further evaluation and confirmation of the findings.
more susceptible to the adverse effect of unsatisfactory
metabolic control than others.
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